Differential hematopoietic cell counts on BM sections in control and TPO-treated WT and Sparc−/− mice
| . | WT saline . | Sparc−/− saline . | WT TPO . | Sparc−/− TPO . | P value of treatment . | P value of host SPARC genotype . |
|---|---|---|---|---|---|---|
| Neutrophils | 81 ± 12.3 | 92.8 ± 11.9 | 143.4 ± 19.9 | 163.8 ± 7.0 | < .0001 | .0208 |
| Eosinophils | 6.6 ± 2.1 | 13.4 ± 3.5 | 8.4 ± 2.9 | 7.6 ± 2.5 | .9315 | .3508 |
| Immature myeloid cells | 26.2 ± 6.3 | 35.8 ± 9.1 | 52 ± 7.6 | 68 ± 9.1 | < .0001 | .0208 |
| Erythroid cells | 69 ± 15.7 | 68.4 ± 13.6 | 65 ± 8.3 | 41.8 ± 6.9 | .0101 | .0375 |
| Megakaryocytes | 10.2 ± 2.8 | 13.4 ± 2.2 | 54.4 ± 8.9 | 65.8 ± 8.7 | .0001 | .0226 |
| Lymphoid cells | 29.8 ± 7.9 | 40.6 ± 12.2 | 50.8 ± 9.1 | 60.8 ± 7.1 | .0001 | .075 |
| . | WT saline . | Sparc−/− saline . | WT TPO . | Sparc−/− TPO . | P value of treatment . | P value of host SPARC genotype . |
|---|---|---|---|---|---|---|
| Neutrophils | 81 ± 12.3 | 92.8 ± 11.9 | 143.4 ± 19.9 | 163.8 ± 7.0 | < .0001 | .0208 |
| Eosinophils | 6.6 ± 2.1 | 13.4 ± 3.5 | 8.4 ± 2.9 | 7.6 ± 2.5 | .9315 | .3508 |
| Immature myeloid cells | 26.2 ± 6.3 | 35.8 ± 9.1 | 52 ± 7.6 | 68 ± 9.1 | < .0001 | .0208 |
| Erythroid cells | 69 ± 15.7 | 68.4 ± 13.6 | 65 ± 8.3 | 41.8 ± 6.9 | .0101 | .0375 |
| Megakaryocytes | 10.2 ± 2.8 | 13.4 ± 2.2 | 54.4 ± 8.9 | 65.8 ± 8.7 | .0001 | .0226 |
| Lymphoid cells | 29.8 ± 7.9 | 40.6 ± 12.2 | 50.8 ± 9.1 | 60.8 ± 7.1 | .0001 | .075 |
Data have been analyzed with a 2-way ANOVA. P value expresses how the treatment (TPO) and the Sparc host genotype affect the variables.